Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …

Background The candidate malaria vaccine RTS, S/AS01E has entered phase 3 trials, but
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Summary Background RTS, S/AS01E is the lead candidate malaria vaccine. We recently
showed efficacy against clinical falciparum malaria in 5–17 month old children, during an …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background Development of an effective malaria vaccine could greatly contribute to disease
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …

ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …

Background The RTS, S/AS malaria vaccine is being developed for delivery through the
World Health Organization's Expanded Program on Immunization (EPI). We assessed the …